Cocrystal Pharma Reports Favorable Preliminary Data from Phase I Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral

Cocrystal Pharma, Inc. reported preliminary results of a Phase I study with CC-42344, a broad-spectrum oral antiviral for the treatment of pandemic and seasonal influenza A, demonstrating a favorable safety and pharmacokinetic profile.